Pasireotide for treating acromegaly

References

• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–382.
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769–4775.
   PubMed Web of Science ®Google Scholar
• Melmed S:. Medical progress: acromegaly. N Engl J Med. 2006;355:2558–2573.
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Salgado LR, et al. Treatment of acromegaly: is there still a place for radiotherapy? Pituitary. 2007;10:53–59.
   PubMed Web of Science ®Google Scholar
• Duarte FH, Jallad RS, Bronstein MD. Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J Clin Endocrinol Metab. 2015;100(5):1863–1869.
   PubMed Web of Science ®Google Scholar
• Puig DM. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf). 2015;83(1):3–14.
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al., et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66:859–868.
   PubMed Web of Science ®Google Scholar
• Colao A, Cappabianca P, Caron P, et al., et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: A randomized, open-label, multicentre study. Clin Endocrinol (Oxf). 2009;70:757–768.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide C2402 study group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomized, phase 3 trial. Lancet Diab Endocrinol. 2014;2:875–884.
   PubMed Web of Science ®Google Scholar
• Patel YC, Murthy KK, Escher EE, et al. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism. 1990;39(9 Suppl 2):63–69.
   PubMed Web of Science ®Google Scholar
• Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997;100:2386–2392.
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.
   PubMed Web of Science ®Google Scholar
• Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab. 2000;85:781–792.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW, Hofland LJ, et al. Somatostatin receptor subtypes in human tumors. Ann Oncol. 2001;12(suppl 2):S31–S36.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Mellemkjaer S, Rasmussen LM, et al. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest. 2001;24:430–437.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010 Mar;21(3):123–133.
   PubMed Web of Science ®Google Scholar
• Eigler T, Ben-Shlomo A. Somatostatin system: molecular mechanisms regulating anterior pituitary hormones. J Mol Endocrinol. 2014;53(1):R1–19.
   PubMed Web of Science ®Google Scholar
• Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009 Jul;94(7):2634–2643.
   PubMed Web of Science ®Google Scholar
• Luque RM, Ibáñez-Costa A, Neto LV, et al. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett. 2015;359(2):299–306.
   PubMed Web of Science ®Google Scholar
• Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995;92(5):1580–1584.
   PubMed Web of Science ®Google Scholar
• Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol. 1996;10(12):1688–1696.
   PubMed Web of Science ®Google Scholar
• Patel YC, Greenwood M, Panetta R, et al. Molecular biology of somatostatin receptor subtypes. Expression of mRNA for all five human somatostatin receptors (hSSTR1–5) in pituitary tumors. Metabolism. 1996;45(8 Suppl 1):31–38.
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156:65–74.
   PubMed Web of Science ®Google Scholar
• Casarini AP, Jallad RS, Pinto EM, et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary. 2009;12(4):297–303.
   PubMed Web of Science ®Google Scholar
• Hornick CA, Anthony CT, Hughey S, et al. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41(7):1256–1263.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836–846.
   PubMedGoogle Scholar
• Schulz S, Lehmann A, Kliewer A, et al. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR review 5. Br J Pharmacol. 2014;171(7):1591–1599.
   PubMed Web of Science ®Google Scholar
• Tulipano G, Stumm R, Pfeiffer M, et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem. 2004;279(20):21374–21382.
   PubMed Web of Science ®Google Scholar
• Liu Q, Cescato R, Dewi DA, et al. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol. 2005;68(1):90–101.
   PubMed Web of Science ®Google Scholar
• Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47(3):502–511.
   PubMed Web of Science ®Google Scholar
• Stroh T, Jackson AC, Sarret P, et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology. 2000;141(1):354–365.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Tani S. Inhibitory action of somatostatin on cAMP dependent pepsinogen secretion from rat gastric chief cells: involvement of pertussis toxin-sensitive G-protein. Biol Pharm Bull. 1994;17(3):415–418.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Cescato R, et al. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab. 2010;95(5):2343–2350.
   PubMed Web of Science ®Google Scholar
• Ferjoux G, Bousquet C, Cordelier P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol. 2000;94:205–210.
   Web of Science ®Google Scholar
• Hubina E, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumors. Eur J Endocrinol. 2006;155:371–379.
   PubMed Web of Science ®Google Scholar
• Lahlou H, Guillermet J, Hortala M, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121–131.
   PubMed Web of Science ®Google Scholar
• Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:1856–1863.
   PubMed Web of Science ®Google Scholar
• Kumar U. Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine. 2011;40(2):168–180.
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733–1742.
   PubMed Web of Science ®Google Scholar
• Pyronnet S, Bousquet C, Najib S, et al. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286(1–2):230–237.
   PubMed Web of Science ®Google Scholar
• Florio T, Barbieri F, Spaziante R, et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer. 2008;15(2):583–596.
   PubMed Web of Science ®Google Scholar
• Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 2004;80(Suppl 1):57–61.
   PubMedGoogle Scholar
• Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf). 2005;63(5):514–519.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Pronin V, Balcere I, LEAD Study Group, et al.. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol. 2015;173(3):313–323.
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–1833.
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren S-G, et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114:349–356.
   PubMed Web of Science ®Google Scholar
• Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet. 1993;25:375–391.
   PubMed Web of Science ®Google Scholar
• Lancranjan I, Bruns C, Grass P, et al., et al. Sandostatin LAR®: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism. 1995;44(Suppl 1):18–26.
   Web of Science ®Google Scholar
• Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1995;80:3267–3272.
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol. 2000;53:719–724.
   PubMed Web of Science ®Google Scholar
• Carmichael JD. Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence. 2012;6:73–82.
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel ® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13:18–28.
   PubMed Web of Science ®Google Scholar
• Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003 Nov;88(11):5258–5265.
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol. 2003;58(4):471–481.
   PubMed Web of Science ®Google Scholar
• Ayuk J, Stewart SE, Stewart PM, et al. Efficacy of SandostatinR LARR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol. 2004;60(3):375–381.
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Salgado LR, et al. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 2005;63(2):168–175.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91(4):1397–1403.
   PubMed Web of Science ®Google Scholar
• Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013 Apr 25;8(4):e61523.
   PubMed Web of Science ®Google Scholar
• Grasso LF, Auriemma RS, Pivonello R, et al. Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf. 2015;14(8):1213–1226.
   PubMed Web of Science ®Google Scholar
• Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology. 2009;90(1):82–92.
   PubMed Web of Science ®Google Scholar
• Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J. 2013;60(4):507–515.
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–716.
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1–2):69–74.
   PubMed Web of Science ®Google Scholar
• Ma P, Wang Y, Van Der Hoek J, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther. 2005;78:69–80.
   PubMed Web of Science ®Google Scholar
• Hipkin RW, Friedman J, Clark RB, et al. Agonist induced desensitization, internalization and phosphorylation of the sst2A somatostatin receptor. J Biol Chem. 1997;272:13869–13876.
   PubMed Web of Science ®Google Scholar
• Pöll F, Lehmann D, Illing S, et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol. 2010;24(2):436–446.
   PubMed Web of Science ®Google Scholar
• Waser B, Cescato R, Liu Q, et al. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients. Am J Pathol. 2012;180(5):1942–1949.
   PubMed Web of Science ®Google Scholar
• Lewis I, Bauer W, Albert R, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003;46(12):2334–2344.
   PubMed Web of Science ®Google Scholar
• Kao YJ, Ghosh M, Schonbrunn A. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol. 2011;25(6):1040–1054.
   PubMed Web of Science ®Google Scholar
• Liu Q, Dewi DA, Liu W, et al. Distinct phosphorylation sites in the sst2A somatostatin receptor control internalization, desensitization, and arrestin binding. Mol Pharmacol. 2008;73(2):292–304.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Van Der Hoek J, Van Koetsveld PM, et al., et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89(4):1577–1585.
   PubMed Web of Science ®Google Scholar
• FDA Website. How to apply for orphan product designation [Internet]. 2014. Available from: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm364750.htm
   Google Scholar
• FDA Website. Pasireotide orphan designation [Internet]. 2014. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=288609
   Google Scholar
• Van Der Hoek J, De Herder WW, Feelders RA, et al., et al A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89(2):638–645.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al., et al Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781–2789.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Farrall AJ, De Block C, et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary. 2014;17(2):132–140.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Bollerslev J, Arafat AM, et al. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol. 2014;54(11):1308–1317.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, Pasireotide C2305 Study Group, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791–799.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Bronstein MD, Freda P, et al. Erratum to: pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary. 2015;18(3):395–396.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174(2):241–250.
   PubMed Web of Science ®Google Scholar
• Zambre Y, Ling Z, Chen MC. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. 1999;57:1159–1164.
   PubMed Web of Science ®Google Scholar
• Singh V, Brendel MD, Zacharias S. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92:673–680.
   PubMed Web of Science ®Google Scholar
• Braun M. The somatostatin receptor in human pancreatic β-cells. Vitam Horm. 2014;95:165–193.
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–3453.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes—2015. Diab Care. 2015;38(Suppl. 1):S41–S48.
   PubMed Web of Science ®Google Scholar
• Murray B, Gordon MD, Spiller KL. MS management of hyperclycemia in a patient with acromegaly treated with pasireotide LAR: a case study AACE Clinical Case Reports. Rapid Electronic Articles in Press; 2015.
   Google Scholar
• Breitschaft A, Hu K, Darstein C, et al. Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single‐center, phase i, randomized, four‐way crossover study. J Clin Pharmacol. 2014;54(1):75–86.
   PubMed Web of Science ®Google Scholar